Servi­er shrugs off a mul­ti­mil­lion-dol­lar in­vest­ment, aban­don­ing a failed MS drug de­vel­oped by GeNeu­ro

Four years af­ter Servi­er paid $44 mil­lion in cash for the op­tion to part­ner with Gene­va-based GeNeu­ro, the French biotech is shrug­ging off the in­vest­ment of time and mon­ey and bow­ing out.

GeNeu­ro says that the move leaves them free to start new part­ner­ing dis­cus­sions for the glob­al rights to GN­bAC1, an ex­per­i­men­tal drug for mul­ti­ple scle­ro­sis which failed a Phase IIb tri­al just 6 months ago. That tri­al, though, set up a $13.5 mil­lion mile­stone for the last pa­tient vis­it that Servi­er was re­quired to cov­er at the be­gin­ning of this year.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER